Xu F - Search Results

1

Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation.

Tian J, Li C, Dong Z, Yang Y, Xing J, Yu P, Xin Y, Xu F, Wang L, Mu Y, Guo X, Sun Q, Zhao G, Gu Y, Qin G, Jiang W. Tian J, et al. Among authors: xu f. Nat Metab. 2023 May;5(5):896-909. doi: 10.1038/s42255-023-00796-w. Epub 2023 May 8. Nat Metab. 2023. PMID: 37157031

2

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).

Du J, Liang L, Fang H, Xu F, Li W, Shen L, Wang X, Xu C, Bian F, Mu Y. Du J, et al. Among authors: xu c, xu f. Diabetes Obes Metab. 2017 Nov;19(11):1513-1520. doi: 10.1111/dom.12942. Epub 2017 Jul 6. Diabetes Obes Metab. 2017. PMID: 28296055 Clinical Trial.

3

Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).

Gao B, Gao W, Wan H, Xu F, Zhou R, Zhang X, Ji Q. Gao B, et al. Among authors: xu f. Diabetes Obes Metab. 2022 Jun;24(6):991-999. doi: 10.1111/dom.14661. Epub 2022 Mar 22. Diabetes Obes Metab. 2022. PMID: 35112779 Free PMC article. Clinical Trial.

4

Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.

Fang H, Xu F, Du J, Liang L, Li W, Shen L, Wang X, Xu C, Bian F, Mu Y. Fang H, et al. Among authors: xu c, xu f. J Diabetes Investig. 2020 Jul;11(4):896-905. doi: 10.1111/jdi.13224. Epub 2020 Mar 27. J Diabetes Investig. 2020. PMID: 32020731 Free PMC article. Clinical Trial.

5

Follow-up frequency and clinical outcomes in patients with type 2 diabetes: A prospective analysis based on multicenter real-world data.

Zhao Q, Li H, Ni Q, Dai Y, Zheng Q, Wang Y, Ke T, Li L, Zhao D, Dong Q, Ji B, Shi J, Peng Y, Zhang Y, Xu F, Wang W. Zhao Q, et al. Among authors: xu f. J Diabetes. 2022 May;14(5):306-314. doi: 10.1111/1753-0407.13271. J Diabetes. 2022. PMID: 35613850 Free PMC article.

6

The effects of economic status on metabolic control in type 2 diabetes mellitus at 10 metabolic management centers in China.

Gu L, Ma Y, Zheng Q, Gu W, Ke T, Li L, Zhao D, Dai Y, Dong Q, Ji B, Xu F, Shi J, Peng Y, Zhang Y, Shen T, Du R, Yang J, Kang M, Peng Y, Wang Y, Wang W. Gu L, et al. Among authors: xu f. J Diabetes. 2024 Jan;16(1):e13466. doi: 10.1111/1753-0407.13466. Epub 2023 Sep 5. J Diabetes. 2024. PMID: 37670495 Free PMC article.

7

Kidney disease parameters, metabolic goal achievement, and arterial stiffness risk in Chinese adult people with type 2 diabetes.

Xu C, Li L, Shi J, Ji B, Zheng Q, Wang Y, Ke T, Li L, Zhao D, Dai Y, Xu F, Peng Y, Zhang Y, Dong Q, Wang W. Xu C, et al. Among authors: xu f. J Diabetes. 2022 May;14(5):345-355. doi: 10.1111/1753-0407.13269. Epub 2022 May 5. J Diabetes. 2022. PMID: 35510608 Free PMC article.

8

Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients.

Zhao L, Zhou X, Chen Y, Dong Q, Zheng Q, Wang Y, Li L, Zhao D, Ji B, Xu F, Shi J, Peng Y, Zhang Y, Dai Y, Ke T, Wang W. Zhao L, et al. Among authors: xu f. J Diabetes. 2024 Jan;16(1):e13463. doi: 10.1111/1753-0407.13463. Epub 2023 Sep 8. J Diabetes. 2024. PMID: 37680102 Free PMC article.

9

[Clinical and electrophysiological characteristics and treatment outcomes of anti-neutrophil cytoplasmic antibody ANCA-associated vasculitic neuropathy].

Li YF, Li M, Yang F, Wang HF, Xu F, Chen SY, Sun B, Chen ZH, Huang XS. Li YF, et al. Among authors: xu f. Zhonghua Nei Ke Za Zhi. 2024 Apr 1;63(4):386-393. doi: 10.3760/cma.j.cn112138-20231031-00267. Zhonghua Nei Ke Za Zhi. 2024. PMID: 38561284 Chinese.

10

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data.

Peng Y, Xu P, Shi J, Zhang Y, Wang S, Zheng Q, Wang Y, Ke T, Li L, Zhao D, Dai Y, Dong Q, Ji B, Xu F, Gu W, Wang W. Peng Y, et al. Among authors: xu p, xu f. J Diabetes. 2022 Feb;14(2):134-143. doi: 10.1111/1753-0407.13245. Epub 2022 Jan 13. J Diabetes. 2022. PMID: 35023626 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,027 results

Search Page